-
EP4094804
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4094804
| EP4094804 - ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 28.10.2022 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 30.07.2021 | Most recent event Tooltip | 06.05.2024 | The date on which the examining division becomes responsible, has been established | 06.05.2024 | Amendment by applicant | Applicant(s) | For all designated states CHUGAI SEIYAKU KABUSHIKI KAISHA 5-1, 5-chome Ukima Kita-ku Tokyo 115-8543 / JP | [2022/48] | Inventor(s) | 01 /
ISSHIKI Yoshiaki c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwara Kamakura-shi, Kanagawa 247-8530 / JP | 02 /
WATANABE Fumio c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135, Komakado 1-chome Gotemba-shi, Shizuoka 412-8513 / JP | 03 /
TOMIZAWA Masaki c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwara Kamakura-shi, Kanagawa 247-8530 / JP | 04 /
HADA Kihito c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwara Kamakura-shi, Kanagawa 247-8530 / JP | 05 /
HATTORI Kazuo c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135, Komakado 1-chome Gotemba-shi, Shizuoka 412-8513 / JP | 06 /
KAWASAKI Kenichi c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwara Kamakura-shi, Kanagawa 247-8530 / JP | 07 /
HYODO Ikumi c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwara Kamakura-shi, Kanagawa 247-8530 / JP | 08 /
AOKI Toshihiro c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwara Kamakura-shi, Kanagawa 247-8530 / JP | [2022/48] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstraße 3 81675 München / DE | [2022/48] | Application number, filing date | 21744061.9 | 21.01.2021 | [2022/48] | WO2021JP02088 | Priority number, date | JP20200008757 | 22.01.2020 Original published format: JP 2020008757 | [2022/48] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021149776 | Date: | 29.07.2021 | Language: | JA | [2021/30] | Type: | A1 Application with search report | No.: | EP4094804 | Date: | 30.11.2022 | Language: | EN | [2022/48] | Search report(s) | International search report - published on: | JP | 29.07.2021 | (Supplementary) European search report - dispatched on: | EP | 16.10.2023 | Classification | IPC: | C07D213/73, C07D213/76, C07D213/81, C07D213/82, C07D305/08, C07D307/14, C07D309/08, C07D333/54, C07D401/06, C07D405/12, C07D409/12, A61K31/166, A61K31/18, A61K31/44, A61K31/4436, A61K31/444, C07C307/10, C07C311/01, A61P35/00, A61P43/00, // C07D471/04, C07C311/08, C07C311/14, C07C311/29, C07C311/49, A61P35/02 | [2023/46] | CPC: |
A61P35/00 (EP,IL,KR);
A61K31/166 (IL,KR);
C07D211/56 (KR);
C07D265/02 (US);
A61K31/18 (IL,KR);
A61K31/24 (KR);
A61K31/44 (IL,KR);
A61K31/4436 (IL,KR);
A61K31/444 (IL,KR);
A61P35/02 (EP);
A61P43/00 (EP,IL);
C07C211/55 (US);
C07C307/02 (US);
C07C307/10 (EP,IL,KR);
C07C311/01 (IL,KR);
C07C311/08 (EP);
C07C311/14 (EP,IL,KR);
C07C311/24 (IL,KR);
C07C311/25 (IL,KR);
C07C311/29 (EP);
C07C311/49 (EP);
C07C317/50 (US);
C07C333/20 (US);
C07C39/26 (US);
C07C69/76 (US);
C07D213/73 (EP,US);
C07D213/74 (US);
C07D213/76 (EP,IL);
C07D213/80 (US);
C07D213/81 (EP);
C07D213/82 (EP);
C07D305/06 (US);
C07D305/08 (EP);
C07D307/10 (IL);
C07D307/14 (EP,KR,US);
C07D307/93 (IL,KR,US);
C07D309/08 (EP,US);
C07D309/14 (US);
C07D333/54 (EP);
C07D333/72 (US);
C07D401/06 (EP,IL,KR);
C07D405/12 (EP,IL,KR,US);
C07D405/14 (US);
C07D409/12 (EP,IL,KR,US);
C07D471/04 (EP,KR,US);
C07F5/027 (US);
C07F7/0812 (US);
C07C2601/02 (EP,IL);
C07C2601/04 (EP,IL)
(-)
|
| Former IPC [2022/48] | A61P35/00, A61P43/00, C07C307/10, C07C311/01, C07D401/06, C07D409/12, C07D213/76, A61K31/166, A61K31/18, A61K31/44, A61K31/4436, A61K31/444 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/48] | Validation states | MA | 11.08.2022 | Title | German: | ARYLAMIDDERIVAT MIT ANTITUMORWIRKUNG | [2022/48] | English: | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | [2022/48] | French: | DÉRIVÉ ARYLAMIDE AYANT UNE ACTIVITÉ ANTITUMORALE | [2022/48] | Entry into regional phase | 11.08.2022 | Translation filed | 11.08.2022 | National basic fee paid | 11.08.2022 | Search fee paid | 11.08.2022 | Designation fee(s) paid | 11.08.2022 | Examination fee paid | Examination procedure | 11.08.2022 | Examination requested [2022/48] | 03.05.2024 | Amendment by applicant (claims and/or description) | 03.05.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 24.01.2023 | Renewal fee patent year 03 | 25.01.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [AD]EP1780197 (CHUGAI PHARMACEUTICAL CO LTD [JP]); | International search | [YA]JP2007511614 ; | [YA]JP2012508203 ; | [YA]JP2016534027 ; | by applicant | WO2006011466 | WO2007091736 |